COLL vs SYK: fair value comparison
Collegium Pharmaceutical, Inc. and Stryker Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, COLL currently sits closer to the top of our discount ranking. SYK carries the stronger quality grade.
| COLL | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $24.00 | $275.56 |
| 12-month range | $24.00–$47.11 | $294.73–$387.02 |
| Sector rank | #16 of 113 Healthcare | #18 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | High | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: COLL fair value analysis · SYK fair value analysis